Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434362 | 0.81 | SLC6A2 (0.34) | CYP2C19SMN1; SMN2CYP3A4 | |
| SCHEMBL988241 | 0.80 | SIGMAR1 (0.39) | CYP2C19CYP1A2HTR2AHRH1ALDH1A1 | |
| SCHEMBL692680 | 0.79 | CYP3A4 (0.42) | CYP2C19SMN1; SMN2CYP1A2HTR2AHRH1 | |
| SCHEMBL10980934 | 0.77 | CYP2C19 (0.37) | CYP2C19HTR2AHRH1KDM4EALDH1A1 | |
| SCHEMBL15841505 | 0.77 | KCNH2 (0.39) | CYP2C19SMN1; SMN2CYP1A2HTR2AHRH1 | |
| SCHEMBL18493238 | 0.76 | TAAR1 (0.39) | CYP2C19SMN1; SMN2HTR2AHRH1KDM4E | |
| SCHEMBL2162784 | 0.76 | CYP2C19 (0.39) | CYP2C19SMN1; SMN2CYP1A2HTR2AHRH1 | |
| SCHEMBL1137366 | 0.76 | HTR2A (0.39) | CYP2C19HTR2AHRH1ALDH1A1TDP1 | |
| SCHEMBL9827793 | 0.76 | DPP4 (0.39) | CYP2C19SMN1; SMN2CYP1A2HTR2AHRH1 | |
| SCHEMBL9285492 | 0.76 | CYP2C19 (0.43) | CYP2C19SMN1; SMN2CYP1A2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667645-A1 | MATERIALS FOR ENHANCED DELIVERY OF HYDROPHILIC ACTIVE AGENTS IN PERSONAL CARE FORMULATIONS | SYMYX TECHNOLOGIES (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1174187-B1 | BIPOLAR MEMBRANE | TOKUYAMA CORP (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-20050152855-A1 | Materials for enhanced delivery of hydrophilic active agents in personal care formulations | FREESLATE, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005027864-A1 | MATERIALS FOR ENHANCED DELIVERY OF HYDROPHILIC ACTIVE AGENTS IN PERSONAL CARE FORMULATIONS | SYMYX TECHNOLOGIES, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-6596137-B2 | Bipolar membrane | TOKOYAMA CORPORATION (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030006138-A1 | Bipolar membrane | TOKUYAMA CORPORATION (JP) | 2003-01-09 | — | — | US | disclosed |
| EP-1174187-A1 | BIPOLAR MEMBRANE | TOKUYAMA CORPORATION (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-0459820-B1 | Bipolar membrane and method for its production | TOKUYAMA CORP (JP) | 1997-07-30 | — | — | EP | disclosed |
| US-5221455-A | A heavy metal-neutralized anionic polymer bonded to a cationic polymer; electrolysis of water; nonbubbling or -foaming at the interface | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1993-06-22 | — | — | US | disclosed |
| EP-0459820-A2 | Bipolar membrane and method for its production | TOKUYAMA CORPORATION (JP) | 1991-12-04 | — | — | EP | disclosed |
| US-4051093-A | Manufacture of shear-resistant aqueous copolymer emulsions | BASF AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050152855-A1 | Materials for enhanced delivery of hydrophilic active agents in personal care formulations | LPO, HAO2, CUTA | CYP2C19 268/4885SMN1; SMN2 1844/4885CYP1A2 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.